胃肠动力药进展及评价  

The progress and evaluation of agents for gastrointestinal motility

作　　者：郭建强[1] 柯美云[1] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院消化内科,北京100730

出　　处：《中国新药杂志》2001年第6期411-415,共5页Chinese Journal of New Drugs

摘　　要：胃肠动力障碍疾病是依其临床症状进行分类的 ,其病理生理机制不明确 ,因此 ,治疗目的为改善临床症状。本文对目前应用调节胃肠道动力药和正在研究的新一代药物的作用机制进行了概括 ,这类药物包括多DA受体阻断剂、苯丙酰胺类和非苯丙酰胺类 5 HT4 受体激动剂和阻断剂、胃动素受体激动剂、NO合酶抑制剂、阿片肽受体阻断剂、GABAB 受体激动剂、CCKA 受体激动剂和生长抑素类似物等。同时对这些药物的临床应用进行了综述和展望。The classfication of gastrointestinal motility diseases is defined on the basis of symptom patterns,for which there is no well-defined pathophysiology and pathogenesis.Therefore,the treatment is aimed at symptoms improvement.In this paper,the pharmacological mechanism of currently available agents and the new generation of agent under development were reviewed.The new agents under development include dopamine receptor antagonist,benzamide and non-benzamide 5-HT 4 receptor agonist and antagonist,motilin receptor agonist,nitric oxide synthase inhibitor,opioid receptor antagonist,GABA B-receptor agonist,CCK A receptor agonist and somatostatin analogues.

关 键 词：胃肠动力疾病 促动力药 动力抑制剂 受体阻断剂 受体类药 生长抑素 

分 类 号：R975[医药卫生—药品]